leadf
logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience orders additional coronavirus studies of antiviral drugs delivered using DehydraTECH

Lexaria has commissioned studies to evaluate DehydraTECH’s ability to enhance the delivery and efficacy of four additional antiviral drugs, including remdesivir

Coronavirus graphic
A previous study demonstrated that DehydraTECH significantly improved drug delivery in animals of two classes of antiviral therapies under investigation for the treatment of the coronavirus

Lexaria Bioscience Corp (OTCQX:LXRP) (CSE:LXX) announced Tuesday that following promising antiviral study results earlier this month, the company has initiated the next phase of research on its DehydraTECH drug delivery platform  

The previous study demonstrated that DehydraTECH significantly improved drug delivery in animals of two classes of antiviral therapies, a protease inhibitor and a reverse transcriptase inhibitor, both of which are under investigation for the treatment of the coronavirus. 

Now, Lexaria has commissioned studies to evaluate DehydraTECH’s ability to enhance the delivery and efficacy of four additional antiviral drugs, including remdesivir, a nucleotide reverse transcriptase inhibitor (NtRTI) approved by the US Food and Drug Administration (FDA) in October for the treatment of coronavirus in cases of hospitalization. 

READ: Lexaria Bioscience closes sale of its non-pharmaceutical THC-related assets to Hill Street Beverage

The studies will administer DehydraTECH-enabled formulations to male rats to quantify and compare total drug delivery into the rodent bloodstream against control formulations. These studies will be conducted by a third-party pharmacokinetic testing laboratory in Pennsylvania, the company said.

An additional study will be undertaken using the services of a separate third-party laboratory to evaluate the relative antiviral activity of certain formulations. Lexaria plans to observe the performance of various formulations in an established cell culture model of SARS-CoV-2 infected cells in an effort to kill the virus. 

This will be the first time one of Lexaria's third-party contracted laboratories will work with live SARS-CoV-2 virus in conjunction with DehydraTECH. If the outcome is positive, the company said it expects to proceed to larger in vivo efficacy testing in animals to determine if DehydraTECH-enabled formulation offers performance enhancements when given orally.

"With these additional antiviral drug studies, we are aggressively expanding and implementing the first of our strategic initiatives for 2021," CEO Chris Bunka said in a statement. "After our recent initial success in animals demonstrating DehydraTECH's ability to enhance drug delivery of two other antiviral drugs, we are excited to work with remdesivir, one of the world's leading drugs currently in use for treatment of COVID-19, to learn whether DehydraTECH may also enhance drug delivery characteristics of NtRTI's."

Lexaria also said it expects to announce its 2021 research and development plans within the next 90 days. If things stay to plan, next year will bring the largest applied R&D program in the company's history.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Lexaria Bioscience Corp.

Price: 7.69 CAD

CSE:LXX
Market: CSE
Market Cap: $39.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

After successful raise of 11 million dollars, Lexaria Bioscience spells out...

Lexaria Bioscience (NASDAQ: LEXXW- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company is planning for a very busy 2021 with a number of research and development initiatives. Bunka telling Proactive they are planning research on DehydraTECH-CBD For Hypertension...

3 weeks, 5 days ago

2 min read